Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05446129
Recruitment Status : Recruiting
First Posted : July 6, 2022
Last Update Posted : May 8, 2023
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:

This study is open to people with newly diagnosed colorectal cancer. People who are scheduled for surgery can participate. People either get a medicine called BI 765063 combined with ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. The tested medicines in this study are antibodies that may help the immune system fight cancer.

The purpose of this study is to find out how well people with early colorectal cancer can tolerate treatment with these medicines. The study also looks at whether the tumor changes.

Participants are put into 2 groups. One group gets ezabenlimab and BI 765063. The other group gets pembrolizumab and BI 765063. All participants receive the study medicines as 2 subsequent infusions into a vein on a single day.

Participants are in the study for about 4 months. During this time, they visit the study site about 5 times. The doctors check the health of the participants and note any health problems that could have been caused by ezabenlimab, pembrolizumab, or BI 765063. The doctors also check whether these health problems lead to a delay of the planned surgery.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: Ezabenlimab Drug: BI 765063 Drug: Pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open Label Study to Assess Safety, Feasibility, Efficacy, and Biological Activity of Single Administration of Neoadjuvant Treatments Ezabenlimab in Combination With BI 765063 and Pembrolizumab in Combination With BI 765063 in Patients With Newly Diagnosed Surgically-resectable, Locoregional Colorectal Cancer
Actual Study Start Date : September 27, 2022
Estimated Primary Completion Date : June 30, 2027
Estimated Study Completion Date : September 30, 2027

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cohort A: Ezabenlimab + BI 765063 Drug: Ezabenlimab

Drug: BI 765063
BI 765063

Experimental: Cohort B: Pembrolizumab + BI 765063 Drug: BI 765063
BI 765063

Drug: Pembrolizumab

Primary Outcome Measures :
  1. Composite endpoint: Proportion of patients with at least one occurrence of a safety or feasibility event [ Time Frame: up to 91 days ]

    Safety is defined as any grade 3 or higher adverse events (according to NCI Common Terminology Criteria for Adverse Event (CTCAE) v5.0) related to study treatments at any point within the follow up period following the administration of study treatments.

    Feasibility or delay in surgery is defined as any treatment related adverse events leading to delay in surgery.

Secondary Outcome Measures :
  1. Pathological response [ Time Frame: up to 91 days ]
    Pathological response defined as at least 50% or more tumor regression classified as per Mandard tumor regression grading system, in viable adenocarcinoma cells in the surgical specimen, including lymph nodes. Pathological response includes complete pathology response (CR), near complete pathological response (near CR) and partial pathological response.

  2. Time from administration of trial treatment to surgery, defined as the time in days that elapses between administration of neoadjuvant trial therapy and surgical resection [ Time Frame: up to 91 days ]
  3. Radiographic response on pre-surgical imaging, following receipt of the neoadjuvant therapy, as per response evaluation criteria in solid tumors (RECIST) v1.1 [ Time Frame: up to 91 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. Ability to understand and the willingness to sign a written informed consent.
  • Male or female aged = 18 years at the time of informed consent form (ICF) signature.
  • Patients with histological diagnosis of resectable colorectal Cancer (CRC), or radiographic/visual findings highly suggestive, with planned confirmatory biopsy.
  • CRC lesions must be at least 1 centimeter (cm) in largest diameter and amenable to endoscopic biopsy.
  • Patient must be willing and able to have endoscopic biopsy (Goal 3-6 core-needle or surgical/endoscopic biopsies, final number to be determined by the physician performing the procedure as safe) of tumor prior to initiation of therapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The exception will be patients with long term disability (such as cerebral palsy) that is unlikely to significantly affect their response to therapy.
  • Patient is determined to be a surgical candidate for resection of their tumor.
  • Adequate organ and marrow function as defined in the protocol.
  • Further inclusion criteria apply.

Exclusion criteria

  • Patients who are deemed to be at high risk for colonic obstruction and/or perforation per investigator assessment.
  • Patients eligible for neoadjuvant therapy (chemotherapy, radiotherapy, chemoradiotherapy) as standard of care.
  • Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to administration of trial medication.
  • Patients who must or wish to continue the intake of restricted medications (as defined in the protocol) or any drug considered likely to interfere with the safe conduct of the trial.
  • Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the patient an unreliable trial participant).
  • Previous enrolment in this trial.
  • Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s) or receiving other investigational treatment(s).
  • Patients who have had chemotherapy or radiotherapy within 6 months prior to entering the study for a different primary tumor, or those that have received locoregional therapy (radiation, chemoembolization, etc.) for the target lesion that will be biopsied and subsequently resected. Previous therapy for a different cancer (a different primary) is acceptable.
  • Prior immune checkpoint inhibitor therapy.
  • Patients with metastatic or recurrent disease, for which the intent of surgery would not be curative.
  • Further exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05446129

Layout table for location contacts
Contact: Boehringer Ingelheim 1-800-243-0127

Layout table for location information
United States, New York
Mount Sinai School of Medicine Recruiting
New York, New York, United States, 10029
Contact: Boehringer Ingelheim    833-602-2368   
Sponsors and Collaborators
Boehringer Ingelheim
Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT05446129    
Other Study ID Numbers: 1502-0001
First Posted: July 6, 2022    Key Record Dates
Last Update Posted: May 8, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action